The Patent Board is a independent provider of best practices research tools and metrics for patent analysis and intellectual property investment. The Board’s ranking evaluates patents issued or applied for over the last 12 months.
This is the second consecutive ranking by The Patent Board of Heska’s intellectual property.
As of Feb. 29, Heska owned, co-owned, or had rights to 184 issued U.S. patents and and three pending patent applications. Heska’s issued and pending patent portfolios primarily relate to heartworm control, flea control, allergy, infectious disease vaccines and diagnostic and detection tests.
The recognition of intellectual property parallels the recognition of scientific innovation, according to Robert Grieve, chairman and CEO of Heska.